Why the study?
Anthracyclines cause cardiotoxicity in pediatric cancer regimens, driving a crucial need to identify effective cardioprotective strategies to mitigate anthracycline-related cardiotoxicity.
Does dexrazoxane prevent anthracycline-related cardiotoxicity in children with cancer?
Does dexrazoxane prevent anthracycline-related cardiotoxicity in children with cancer?
This position statement recommends considering the routine use of dexrazoxane to mitigate anthracycline-related cardiotoxicity in pediatric cancer patients.
No takes yet. Share an insight, caveat, or question.
May support routine dexrazoxane in pediatric anthracycline regimens; extends literature synthesis into formal guideline recommendation.
Bertorello et al. (2023) studied this question.